

Turn your real-world data into compelling evidence that accelerates regulatory approvals, strengthens payer negotiations, and validates outcomes. We bring real-world data together with methodological rigor, deep therapeutic expertise, and intelligent insights.
IQVIA curates and integrates fit-for-purpose real-world data with methodological rigor and therapeutic expertise. As a data-agnostic partner, we generate regulatory-grade RWE that drives submissions, market access, and adoption across lifecycles.
IQVIA is data agnostic—we match the right data source to your scientific and regulatory requirements. Our comprehensive longitudinal datasets cover over 318M U.S. lives, spanning claims, EMRs, patient-reported outcomes, and real-world wearables data.
IQVIA's regulatory experts include former FDA reviewers and senior health economists who help navigate complex regulatory landscapes. Our team understands evolving FDA requirements and helps strengthen submissions through established regulatory precedents.
AI-assisted solutions reduce manual literature review efforts by 70%. Our Healthcare-grade AI™ powers comprehensive literature analysis, evidence synthesis, and research acceleration to deliver faster, more relevant insights.
Generate evidence that resonates across stakeholders - from cost-effectiveness studies for payers to HCP-relevant efficacy data. We help translate RWE into targeted communications for HTAs, payers, and providers in value-based care.
Operating in 100+ countries with deep regulatory filing expertise, IQVIA delivers RWE studies that meet global regulatory standards. Our best-practice approach ensures studies align with country-specific regulatory requirements and payer expectations.
IQVIA’s unmatched data network, deep regulatory experience, and AI-powered tools are transforming how life sciences companies generate evidence, support approvals, and streamline research—all while maintaining scientific rigor and speed.
Claims and EMR data live in IQVIA data network – more than any other provider.
RWE regulatory interactions in the past 3 years across global markets.
FDA approvals supported by IQVIA RWD assets since 2020.
Reduction in literature review time achieved by AI, while maintaining quality.
From PharMetrics® Plus data to AI-powered analytics, IQVIA delivers the industry's most comprehensive RWE ecosystem.
Learn how IQVIA Healthcare-grade AI identified patients at high risk of stroke, enabled targeted interventions and personalized care plans.
Learn how the CDC utilized our solution to rapidly gain insights on hypertension
IQVIA’s expert guidance and advanced methodologies can enhance the design of external comparators for regulatory decisions